We provide the latest news
from the world of economics and finance
(RTTNews) - Candel Therapeutics, Inc. (CADL), Thursday announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CAN-2409, for the treatment of pancreatic cancer.
The designation comes as Candel reported the updated overall survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir, showing that multiple injections of CAN-2409 were well tolerated among the participants, with no dose-limiting toxicities and no cases of pancreatitis.
Earlier, FDA had granted Fast Track Designation to the program, the company added.
Currently, Candel's stock is climbing 21.96 percent, to $6.21 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.